Results 91 to 100 of about 49,152 (197)

Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte Subpopulations

, 2000
Up to 60% of patients receiving their first infusion of the bisphosphonate pamidronate experience an acute-phase reaction. In this study, we used flow cytometry to determine the effects of pamidronate treatment on circulating lymphocyte subpopulations ...
Sauty, A., Andrea Vera Keck, Martin Pecherstorfer, Zimmer-Roth, I., Keck, A. V., Eva Horn, Horn, E., Daniel Thiebaud, Ilse Zimmer-Roth, Jilch, R., Pecherstorfer, M., Ruth Jilch, Thiebaud, D., Alain Sauty   +13 more
core   +1 more source

INTRAVENOUS PAMIDRONATE IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CHRONIC CRITICAL ILLNESS.

, 2016
OBJECTIVE: Chronic critical illness (CCI), characterized by prolonged mechanical ventilation and tracheostomy, commonly manifests with elevated bone resorption, which has previously been shown to abate after treatment with intravenous (IV ...
Moshier, Erin L, Godbold, James H, Mechanick, Jeffrey I, Zaidi, Mone, Schulman, Rifka C, Rho, Lisa, Casey, Martin F   +6 more
core   +1 more source

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid

Haematologica, 2006
Osteonecrosis of the jaw (ONJ) has been associated with the use of pamidronate and zoledronic acid. ONJ was assessed prospectively since July 2003 in 202 patients with multiple myeloma (MM) who received bisphosphonates since April 1995. Fifteen patients (
MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, LA Moulopoulos, C Bamia, E Terpos, K Tsionos, A Bamias   +9 more
doaj  

Response to alendronate in osteoporotic women previously treated with pamidronate

, 2003
INTRODUCTION: Different bisphosphonates have been shown to increase bone mineral density (BMD) and reduce the risk of fracture in osteoporotic patients.
Fuss, Michel, Fellemans, C., Bergmann, Pierre, Rozenberg, Serge, Siderova, Vania, Peretz, Anne, Body, Jean-Jacques, Dumon, Jean Claude   +7 more
core  

The Effect of Locally Administered Pamidronate on Autogenous Bone Graft in Maxillofacial Reconstruction: A Randomized Clinical Trial

International Journal of Organ Transplantation Medicine, 2017
Background: Although bone grafts are commonly used in reconstructive surgeries, they are sensitive to local perfusion and are thus prone to severe resorption.
M Bayat, A Garajei, E Afshari Pour, M Hasheminasab, Y Ghorbani, MH Kalantar Motamedi, N Bahrami   +6 more
doaj  

Pamidronate for SAPHO syndrome [PDF]

Rheumatology, 2003
openaire   +2 more sources

Evaluation of adverse experiences related to pamidronate infusion in Paget’s disease of bone.

, 1998
Pamidronate disodium, a second generation bisphosphonate, has been found to be safe as well as effective in the treatment of Paget's disease of bone.1 It is licensed in the UK and many other countries for the intravenous treatment of Paget's disease ...
Richardson, P. C., Davison, C. E., Mercer, S. J., Hollis, Sally, Buckler, H. M.   +4 more
core   +1 more source

The use of subcutaneous pamidronate [PDF]

Journal of Pain and Symptom Management, 2003
openaire   +2 more sources

Evaluation of Two Different Pamidronate Treatment Protocols in Children with Osteogenesis Imperfecta

Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2014
Purpose: Osteogenesis imperfecta is an inherited disorder of connective tissue. Children with this condition suffer from recurrent fractures, deformities, osteoporosis and pain.
Neslihan Onenli Mungan, Fatih Gurbuz, Eda Mengen, Ozden Ozgur, Ali Kemal Topaloglu, Bilgin Yuksel   +5 more
doaj  

(The) role of pamidronate in osteoblastic differentiation of human mesenchymal stem cell

, 2004
의과학과/석사[한글] 골수 내에 존재하는 간엽 줄기세포는 골아세포, 연골세포, 지방세포, 근육세포, 신경세포 등의 다양한 결체 조직으로 분화할 수 있는 능력을 가진 것으로 알려져 있으며 실험실에서의 연구와 동물실험으로부터 그 가능성이 증명되었다. Bisphosphonates는 골 흡수가 야기되는 질환의 치료제로 임상에서 폭 넓게 사용되고 있는 물질로, 파골세포의 활성을 저해시킨다.
류주경
core